Compare Morgan Stanley (MS) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Morgan Stanley vs Viatris Inc — how do they compare? Morgan Stanley trades at $188.6 (market cap $294.39B), while Viatris Inc trades at $17.47 (market cap $20.03B). The key difference: Morgan Stanley is far larger — about 14.7× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.75%). Which is the better fit depends on your goals — on Pluang, investors hold Morgan Stanley for 93 Days and Viatris Inc for 57 Days on average.
| MS | VTRS | |
|---|---|---|
Market Cap | $294.39B | $20.03B |
Volume | 5,836,423 | 14,109,977 |
Sector | Financials | Health |
52-Week High | $228.42 | $18.27 |
52-Week Low | $151.86 | $9.74 |
Typical Hold Time | 93 Days | 57 Days |
Enterprise Value | $660.04B | $32.15B |
Dividend Yield | 2.45% | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Morgan Stanley (MS) trades at $187.41, down 1.86% on the day, with a bearish technical signal but strong fundamentals including a P/E of 15.32 and net income margin of 27.59%. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue growth is robust, rising from $50.2B in 2022 to $66.0B in 2025, and the company highlights growth opportunities in wealth management and AI financing.
The outlook is supported by a bullish analyst consensus with a $229.25 price target, though risks include volatile cash flows and rising debt-to-asset ratios. Near-term price action is testing support near $184, with investor sentiment mixed amid fading capital markets momentum but positive long-term growth narratives.
Viatris (VTRS) trades at $17.49, down 0.29% with a bullish technical signal and strong recent earnings beats. The company shows improving operational cash flow of $2.32B in 2025 and positive revenue growth trends, though profitability remains challenged with negative net margins. Recent developments include FDA approval for WAKIX in Japan and consistent dividend payments, supporting the bullish analyst consensus with a $22.17 price target representing 27% upside potential.
The outlook remains cautiously optimistic with strong cash generation supporting shareholder returns, but investors face risks from persistent negative profitability and high debt levels. The stock offers value appeal with reasonable P/S and P/B ratios, though the elevated P/E ratio reflects current earnings challenges that need resolution for sustained re-rating.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Morgan Stanley
Morgan Stanley is a global investment bank whose history, through its legacy firms, can be traced back to 1924. The company has institutional securities, wealth management, and investment management segments. The company had about $5 trillion of client assets as well as over 70,000 employees at the end of 2021. Approximately 50% of the company's net revenue is from its institutional securities business, with the remainder coming from wealth and investment management. The company derives about 30% of its total revenue outside the Americas.
Read more on MS →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
